Moreover, the dual inhibition of BCR-ABL and ULK1 in animal models restored the normal ratio of immature myeloid and erythroid cells in the bone marrow and effectively targeted therapy-resistant CML leukemic stem cells. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.